Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?

McMartin C, Lacombe L, Fradet V, Fradet Y, Lodde M, Toren P.

Clin Genitourin Cancer. 2019 Aug 5. pii: S1558-7673(19)30244-7. doi: 10.1016/j.clgc.2019.07.016. [Epub ahead of print]

PMID:
31594737
2.

Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients.

Joncas FH, Lucien F, Rouleau M, Morin F, Leong HS, Pouliot F, Fradet Y, Gilbert C, Toren P.

Prostate. 2019 Nov;79(15):1767-1776. doi: 10.1002/pros.23901. Epub 2019 Sep 2.

PMID:
31475741
3.

Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.

Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P.

Eur Urol Oncol. 2019 Jan 30. pii: S2588-9311(19)30010-0. doi: 10.1016/j.euo.2019.01.009. [Epub ahead of print]

PMID:
31411963
4.

Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis.

Atchia KS, Wallis CJD, Fleshner N, Toren P.

Can Urol Assoc J. 2019 Jul 23. doi: 10.5489/cuaj.5996. [Epub ahead of print]

PMID:
31348745
5.

Standardization of In Vitro Testing During Development of Abuse-Deterrent Opioids: Highlights From the Second and Third Category 1 Focus Group Meetings.

Elhauge T, Schwier S, Hoag SW, Setnik B, Bianchi R, Altomare C, Toren P, Lindhardt K.

Pain Pract. 2019 Jul;19(6):580-585. doi: 10.1111/papr.12778. No abstract available.

PMID:
31286642
6.

PEG10 is associated with treatment-induced neuroendocrine prostate cancer.

Kim S, Thaper D, Bidnur S, Toren P, Akamatsu S, Bishop JL, Colins C, Vahid S, Zoubeidi A.

J Mol Endocrinol. 2019 Jul 1;63(1):39-49. doi: 10.1530/JME-18-0226.

PMID:
31013476
7.

Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series.

Haider M, Ladurner C, Mayr R, Tandogdu Z, Fritsche HM, Fradet V, Comploj E, Pycha A, Lemire F, Lacombe L, Fradet Y, Toren P, Lodde M.

Urol Oncol. 2019 May;37(5):300.e9-300.e15. doi: 10.1016/j.urolonc.2019.01.017. Epub 2019 Mar 12.

PMID:
30871997
8.

Images - Sclerosing mesenteritis presenting with unilateral hydro-ureteronephrosis.

Turcotte B, Toren P, Cloutier J.

Can Urol Assoc J. 2019 Jan 21:E306-E308. doi: 10.5489/cuaj.5689. [Epub ahead of print] No abstract available.

9.

Discordance between testosterone measurement methods in castrated prostate cancer patients.

Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F.

Endocr Connect. 2019 Jan 1. pii: EC-18-0476. doi: 10.1530/EC-18-0476. [Epub ahead of print]

10.

Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial.

Toren P, Hoffman A, Ding K, Joncas FH, Turcotte V, Caron P, Pouliot F, Fradet Y, Lévesque É, Guillemette C, Klotz L.

Clin Cancer Res. 2018 Nov 1;24(21):5305-5312. doi: 10.1158/1078-0432.CCR-18-1187. Epub 2018 Jul 18.

11.

Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer.

Pelletier J, Cyr SJ, Julien AS, Fradet Y, Lacombe L, Toren P.

Urol Oncol. 2018 Aug;36(8):363.e7-363.e11. doi: 10.1016/j.urolonc.2018.05.004. Epub 2018 Jun 5.

PMID:
29880461
12.

Tyr1-ψ[( Z)CF═CH]-Gly2 Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin.

Altman RA, Sharma KK, Rajewski LG, Toren PC, Baltezor MJ, Pal M, Karad SN.

ACS Chem Neurosci. 2018 Jul 18;9(7):1735-1742. doi: 10.1021/acschemneuro.8b00085. Epub 2018 Apr 19.

13.

Psychiatric disorders and compliance with prenatal care: A 10-year retrospective cohort compared to controls.

Ben-Sheetrit J, Huller-Harari L, Rasner M, Magen N, Nacasch N, Toren P.

Eur Psychiatry. 2018 Mar;49:23-29. doi: 10.1016/j.eurpsy.2017.11.011. Epub 2018 Jan 30.

PMID:
29353177
14.

Label-Free Optical Biodetection of Pathogen Virulence Factors in Complex Media Using Microtoroids with Multifunctional Surface Functionality.

Toren P, Ozgur E, Bayindir M.

ACS Sens. 2018 Feb 23;3(2):352-359. doi: 10.1021/acssensors.7b00775. Epub 2018 Jan 30.

PMID:
29336141
15.

Sex steroids in the tumor microenvironment and prostate cancer progression.

Boibessot C, Toren P.

Endocr Relat Cancer. 2018 Mar;25(3):R179-R196. doi: 10.1530/ERC-17-0493. Epub 2018 Jan 9. Review.

PMID:
29317479
16.

Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.

Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y.

BJU Int. 2018 Mar;121(3):399-404. doi: 10.1111/bju.14041. Epub 2017 Oct 25.

17.

Predictors of Clinical Outcomes in Sexually Abused Adolescents.

Tocker L, Ben-Amitay G, Horesh-Reinman N, Lask M, Toren P.

J Child Sex Abus. 2017 May-Jun;26(4):487-505. doi: 10.1080/10538712.2017.1300204.

PMID:
28537850
18.

Analysis of the translatome in solid tumors using polyribosome profiling/RNA-Seq.

Adjibade P, Grenier St-Sauveur V, Droit A, Khandjian EW, Toren P, Mazroui R.

J Biol Methods. 2016 Nov 21;3(4):e59. doi: 10.14440/jbm.2016.151. eCollection 2016.

19.

Oligonucleotide-based label-free detection with optical microresonators: strategies and challenges.

Toren P, Ozgur E, Bayindir M.

Lab Chip. 2016 Jul 5;16(14):2572-95. doi: 10.1039/c6lc00521g. Review.

PMID:
27306702
20.

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.

Toren P, Kim S, Johnson F, Zoubeidi A.

PLoS One. 2016 Apr 5;11(4):e0152861. doi: 10.1371/journal.pone.0152861. eCollection 2016.

21.

Psychophysiological Reactivity in Child Sexual Abuse.

Ben-Amitay G, Kimchi N, Wolmer L, Toren P.

J Child Sex Abus. 2016;25(2):185-200. doi: 10.1080/10538712.2016.1124309.

PMID:
26934544
22.

Assessing the Use of the Child Attachment Interview in a Sample of Israeli Jewish Children.

Baumel A, Wolmer L, Laor N, Toren P.

Isr J Psychiatry Relat Sci. 2016;53(3):56-61.

23.

Real-Time and Selective Detection of Single Nucleotide DNA Mutations Using Surface Engineered Microtoroids.

Toren P, Ozgur E, Bayindir M.

Anal Chem. 2015 Nov 3;87(21):10920-6. doi: 10.1021/acs.analchem.5b02664. Epub 2015 Oct 22.

PMID:
26457918
24.

Label-Free Biosensing with High Selectivity in Complex Media using Microtoroidal Optical Resonators.

Ozgur E, Toren P, Aktas O, Huseyinoglu E, Bayindir M.

Sci Rep. 2015 Aug 14;5:13173. doi: 10.1038/srep13173.

25.

Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.

Klotz L, O'Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, Horwitz E, Malone S, Goldenberg L, Gospodarowicz M, Crook JM.

J Clin Oncol. 2015 Apr 1;33(10):1151-6. doi: 10.1200/JCO.2014.58.2973. Epub 2015 Mar 2. Erratum in: J Clin Oncol. 2016 Jun 1;34(16):1965.

26.

Active surveillance in patients with a PSA >10 ng/mL.

Toren P, Wong LM, Timilshina N, Alibhai S, Trachtenberg J, Fleshner N, Finelli A.

Can Urol Assoc J. 2014 Sep;8(9-10):E702-7. doi: 10.5489/cuaj.2121.

27.

Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.

Toren PJ, Kim S, Pham S, Mangalji A, Adomat H, Guns ES, Zoubeidi A, Moore W, Gleave ME.

Mol Cancer Ther. 2015 Jan;14(1):59-69. doi: 10.1158/1535-7163.MCT-14-0521. Epub 2014 Oct 28.

28.

Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.

Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, Gleave ME, Zoubeidi A.

Eur Urol. 2015 Jun;67(6):986-990. doi: 10.1016/j.eururo.2014.08.006. Epub 2014 Aug 20.

PMID:
25151012
29.

Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer.

Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, Fazli L, Lamoureux F, Gust KM, Cox ME, Bishop JL, Zoubeidi A.

Oncogenesis. 2014 Aug 18;3:e115. doi: 10.1038/oncsis.2014.30.

30.

Impact of environmental and personality factors upon adolescents before and after psychotherapeutic intervention.

Mittler S, Horesh N, Maytal HR, Toren P.

Compr Psychiatry. 2014 Nov;55(8):1791-802. doi: 10.1016/j.comppsych.2014.07.014. Epub 2014 Jul 21.

PMID:
25125378
31.

Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review).

Toren P, Zoubeidi A.

Int J Oncol. 2014 Nov;45(5):1793-801. doi: 10.3892/ijo.2014.2601. Epub 2014 Aug 14. Review.

PMID:
25120209
32.

Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study.

Santa Mina D, Connor MK, Alibhai SM, Toren P, Guglietti C, Matthew AG, Trachtenberg J, Ritvo P.

Can Urol Assoc J. 2013 Nov-Dec;7(11-12):E692-8. doi: 10.5489/cuaj.235.

33.

Periprostatic adipose tissue and prostate cancer progression: new insights into the tumor microenvironment.

Toren P, Venkateswaran V.

Clin Genitourin Cancer. 2014 Feb;12(1):21-6. doi: 10.1016/j.clgc.2013.07.013. Epub 2013 Oct 24. Review. No abstract available.

PMID:
24269373
34.

Label-free nanometer-resolution imaging of biological architectures through surface enhanced Raman scattering.

Ayas S, Cinar G, Ozkan AD, Soran Z, Ekiz O, Kocaay D, Tomak A, Toren P, Kaya Y, Tunc I, Zareie H, Tekinay T, Tekinay AB, Guler MO, Dana A.

Sci Rep. 2013;3:2624. doi: 10.1038/srep02624.

35.

Novel non-AR therapeutic targets in castrate resistant prostate cancer.

Toren PJ, Gleave ME.

Transl Androl Urol. 2013 Sep;2(3):265-77. doi: 10.3978/j.issn.2223-4683.2013.09.09. Review.

36.

Results of a national population-based study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus.

Toren P, Abouassaly R, Timilshina N, Kulkarni G, Alibhai S, Finelli A.

Urology. 2013 Sep;82(3):572-7. doi: 10.1016/j.urology.2013.04.054.

PMID:
23987150
37.

Rational cotargeting of Pim-1 and Akt in prostate cancer.

Toren P, Zoubeidi A.

Expert Rev Anticancer Ther. 2013 Aug;13(8):937-9. doi: 10.1586/14737140.2013.816461.

PMID:
23984895
38.

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.

Toren P, Margel D, Kulkarni G, Finelli A, Zlotta A, Fleshner N.

BMJ. 2013 Apr 15;346:f2109. doi: 10.1136/bmj.f2109.

39.

Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer.

Toren PJ, Gleave ME.

Asian J Androl. 2013 May;15(3):342-9. doi: 10.1038/aja.2013.38. Epub 2013 Apr 15. Review.

40.

Re: Shilo Y, Zisman A, Lindner A, et al. The predominance of benign histology in small testicular masses. Urol Oncol 2012;30:719-22.

Toren P, Lo K.

Urol Oncol. 2013 Apr;31(3):392. doi: 10.1016/j.urolonc.2012.11.018. Epub 2013 Feb 6. No abstract available.

PMID:
23395240
41.

Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?

Klotz L, Toren P.

Curr Oncol. 2012 Dec;19(Suppl 3):S13-21. doi: 10.3747/co.19.1298.

42.

Diet, obesity, and cancer progression: are adipocytes the link?

Toren P, Mora BC, Venkateswaran V.

Lipid Insights. 2013 Jun 27;6:37-45. doi: 10.4137/LPI.S10871. eCollection 2013. Review.

43.

High-resolution mass spectrometry elucidates metabonate (false metabolite) formation from alkylamine drugs during in vitro metabolite profiling.

Barbara JE, Kazmi F, Muranjan S, Toren PC, Parkinson A.

Drug Metab Dispos. 2012 Oct;40(10):1966-75. doi: 10.1124/dmd.112.047027. Epub 2012 Jul 13.

PMID:
22798552
44.

Platelet vesicular monoamine transporter 2 density in the disruptive behavior disorders.

Zalsman G, Aslanov-Farbstein D, Rehavi M, Roz N, Vermeiren R, Laor N, Weizman A, Toren P.

J Child Adolesc Psychopharmacol. 2011 Aug;21(4):341-4. doi: 10.1089/cap.2010.0148.

PMID:
21851191
45.

Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records.

Bostrom PJ, Toren PJ, Xi H, Chow R, Truong T, Liu J, Lane K, Legere L, Chagpar A, Zlotta AR, Finelli A, Fleshner NE, Grober ED, Jewett MA.

J Am Med Inform Assoc. 2011 Nov-Dec;18(6):835-41. doi: 10.1136/amiajnl-2011-000221. Epub 2011 Aug 4.

46.

The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.

Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P, Parkinson A.

Drug Metab Dispos. 2011 Nov;39(11):2020-33. doi: 10.1124/dmd.111.041293. Epub 2011 Jul 27.

PMID:
21795468
47.

An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes.

Parkinson A, Kazmi F, Buckley DB, Yerino P, Paris BL, Holsapple J, Toren P, Otradovec SM, Ogilvie BW.

Drug Metab Dispos. 2011 Aug;39(8):1370-87. doi: 10.1124/dmd.111.038596. Epub 2011 Apr 27.

PMID:
21525169
48.

Altered affinity of the platelet vesicular monoamine transporter 2 to dihydrotetrabenazine in children with major depression.

Zalsman G, Rehavi M, Roz N, Laor N, Weizman A, Toren P.

J Neural Transm (Vienna). 2011 Sep;118(9):1383-7. doi: 10.1007/s00702-011-0643-4. Epub 2011 Apr 12.

PMID:
21484276
49.

Use of a novel parenchymal clamp for laparoscopic and open partial nephrectomy.

Toren P, Al-Essawi T, McLean A, Jain U.

Can Urol Assoc J. 2010 Oct;4(5):E133-6.

50.

Brief parent-child group therapy for childhood anxiety disorders: a developmental perspective on cognitive-behavioral group treatment.

Ben-Amitay G, Rosental B, Toren P.

Int J Group Psychother. 2010;60(3):389-406. doi: 10.1521/ijgp.2010.60.3.389.

PMID:
20590435

Supplemental Content

Support Center